1. Nat Commun. 2024 Nov 25;15(1):10217. doi: 10.1038/s41467-024-54460-2.

Modified FOLFOXIRI plus cetuximab versus bevacizumab in RAS wild-type metastatic 
colorectal cancer: a randomized phase II DEEPER trial.

Shiozawa M(#)(1), Sunakawa Y(#)(2), Watanabe T(3), Ota H(4), Yasui H(5), Yabuno 
T(6), Tei M(7), Kochi M(8), Manaka D(9), Ohori H(10), Yamaguchi T(11), Sagawa 
T(12), Kotaka M(13), Kubota Y(14), Sekikawa T(15), Nakamura M(16), Takeuchi 
M(17), Ichikawa W(15), Fujii M(18), Tsuji A(19).

Author information:
(1)Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, 
Japan.
(2)Department of Clinical Oncology, St. Marianna University School of Medicine, 
Kawasaki, Japan. y.suna0825@gmail.com.
(3)Department of Surgery, Tokushima Municipal Hospital, Tokushima, Japan.
(4)Department of Gastroenterological Surgery, Ikeda City Hospital, Ikeda, Japan.
(5)Department of Medical Oncology, Kobe City Medical Center General Hospital, 
Kobe, Japan.
(6)Department of Gastroenterological Surgery, Yokohama Municipal Citizen's 
Hospital, Yokohama, Japan.
(7)Department of Surgery, Osaka Rosai Hospital, Osaka, Japan.
(8)Department of Hepato-Biliary-Pancreatic and Gastrointestinal Surgery, 
International University of Health and Welfare, School of Medicine, Otawara, 
Japan.
(9)Department of Surgery, Gastro-Intestinal Center, Kyoto Katsura Hospital, 
Kyoto, Japan.
(10)Department of Medical Oncology, Ishinomaki Red Cross Hospital, Ishinomaki, 
Japan.
(11)Department of Clinical Genetics, Tokyo Metropolitan Cancer and Infectious 
Diseases Center, Komagome Hospital, Tokyo, Japan.
(12)Division of Gastroenterology, National Hospital Organization Hokkaido Cancer 
Center, Sapporo, Japan.
(13)Gastrointestinal Cancer Center, Sano Hospital, Kobe, Japan.
(14)Department of Clinical Oncology, Showa University Hospital, Tokyo, Japan.
(15)Division of Medical Oncology, Showa University Fujigaoka Hospital, Yokohama, 
Japan.
(16)Aizawa Comprehensive Cancer Center, Aizawa Hospital, Matsumoto, Japan.
(17)Graduate School of Mathematical Sciences, The University of Tokyo, Tokyo, 
Japan.
(18)Japan Clinical Cancer Research Organization, Tokyo, Japan.
(19)Department of Clinical Oncology, Faculty of Medicine, Kagawa University, 
Kagawa, Japan.
(#)Contributed equally

The clinical significance of FOLFOXIRI (5-FU, leucovorin, oxaliplatin, and 
irinotecan) plus anti-EGFR monoclonal antibody using cetuximab for metastatic 
colorectal cancer (mCRC) remains controversial. We report results from a 
randomized phase 2 DEEPER trial (UMIN000018217, jRCTs061180022) to test the 
superiority of modified (m)-FOLFOXIRI plus weekly cetuximab over bevacizumab in 
patients with RAS wild-type (wt) mCRC. Primary endpoint was depth of response 
(DpR). Secondary endpoints included objective response rate (ORR), early tumor 
shrinkage (ETS) at week 8, progression-free survival (PFS), overall survival 
(OS), time to tumor growth (TTG), time to treatment failure (TTF), association 
between tumor shrinkage and prognosis, association between TTG and prognosis, R0 
resection rate, and safety. In 359 enrolled patients with RAS wt mCRC, median 
DpR was significantly better in cetuximab (57.3% vs 46.0%, p = 0.0029); however, 
ORR, ETS, R0 resection rate, TTG, TTF, PFS and OS were similar between 2 
treatments. There was a weak association between DpR and survival time in both 
treatments. The correlation between TTG and OS was slightly stronger in 
cetuximab. The post-hoc exploratory analysis showed that cetuximab produced 
greater PFS (15.3 vs 11.7 months; HR 0.68) and OS (53.6 vs 40.2 months; HR 0.54) 
in patients with left-sided and RAS/BRAF wt tumors. m-FOLFOXIRI plus cetuximab 
has clinical benefit for tumor shrinkage in RAS wt mCRC. The survival benefit 
for RAS/BRAF wt and left-sided mCRC needs further investigation.

© 2024. The Author(s).

DOI: 10.1038/s41467-024-54460-2
PMCID: PMC11589592
PMID: 39587053 [Indexed for MEDLINE]

Conflict of interest statement: Competing interests: M.S. has received honoraria 
from Chugai Pharmaceutical Co., Ltd, Eli Lilly Japan K.K., Takeda Co., Ltd, 
Taiho Pharmaceutical Co., Ltd, Merck Biopharma Co., Ltd, Ono Pharmaceutical Co., 
Ltd, Johnson & Johnson K.K, Kaken Pharmaceutical Co., Ltd. Y.S. has received 
honoraria from Eli Lilly Japan K.K., Bristol-Myers Squibb K.K., Chugai 
Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ono Pharmaceutical Co., 
Ltd., Merck Biopharma Co., Ltd., Taiho Pharmaceutical Co., Ltd., Bayer Yakuhin, 
Ltd., Daiichi Sankyo Co., Ltd., MSD K.K., Novartis Pharmaceuticals, Astellas 
Pharma Inc., Sysmex, and Guardant Health, and has also received grants from 
Chugai Pharmaceutical Co., Ltd. and Taiho Pharmaceutical Co., Ltd. T.Y. has 
received honoraria from Chugai Pharmaceutical Co., Ltd, Taiho Pharmaceutical 
Co., Ltd, FALCO Biosystems Ltd, Asahi Kasei Pharma Corporation Co., Ltd, Eli 
Lilly Japan K.K., Ono Pharmaceutical Co., Ltd. M.K. has received honoraria from 
Chugai Pharmaceutical Co., Ltd, Eli Lilly Japan K.K., Takeda Co., Ltd, Taiho 
Pharmaceutical Co., Ltd, Yakult Honsha Co., Ltd. M.N. has received honoraria 
from Bayer Co., Ltd, Chugai Pharmaceutical Co., Ltd, Daiichi Sankyo Co., Ltd, 
Eli Lilly Japan K.K., Merck Bio Pharma Co., Ltd, MSD K.K., Nihon Servier Co., 
Ltd, Ono Pharmaceutical Co., Ltd, Taiho Pharmaceutical Co., Ltd, Takeda Co., 
Ltd, and Yakult Honsha Co., Ltd. W.I. has received honoraria from Taiho 
Pharmaceutical Co., Ltd, Chugai Pharmaceutical Co., Ltd, Daiichi Sankyo Co., 
Ltd, Takeda Pharmaceutical Co., Ltd, Ono Pharmaceutical Co., Ltd, Merck 
Biopharma Co., Ltd, Yakult Honsha Co., Ltd, Bristol-Myers Squibb K.K., 
AstraZeneca K.K., Kyowa Kirin Co., Ltd, MSD K.K,., Nippon Kayaku Co., Ltd, and 
grants from Taiho Pharmaceutical Co., Ltd, Chugai Pharmaceutical Co., Ltd, 
Daiichi Sankyo Co., Ltd, Shionogi & Co., Ltd, Takeda Pharmaceutical Co., Ltd, 
Ono Pharmaceutical Co., Ltd, and Merck. A.T. has received honoraria from Taiho 
Pharmaceutical Co., Ltd, Chugai Pharmaceutical Co., Ltd, Eli Lilly Japan K.K., 
Merck Serono Co., Ltd, Sanofi K.K., Bristol-Myers Squibb K.K. All other authors 
declare no competing interests.